For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$2.45
Thesis
Recursion Pharmaceuticals runs an industrialized, automated biology platform that generates large datasets to train machine-learning models for drug discovery. Its scale and pharma partnerships aim to convert data advantages into a clinical pipeline.
Catalysts
- Clinical-stage program readouts
- Partnership milestone and option payments
- Demonstrating platform-driven pipeline productivity
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 20OtherClinicalTrials.gov
ClinicalTrials.gov update for NCT05985655 (GTAEXS617, Phase 1/2, advanced solid tumors): status changed to ACTIVE_NOT_RECRUITING; sponsored by Exscientia AI Ltd
- Nov 2Financial resultsSEC
8-K filing disclosing Q3 financial results (item 2.02) and leadership changes (item 5.02).
- Oct 15Securities offeringSEC
Recursion Pharmaceuticals filed Form 424B5 prospectus supplement.
- Oct 15OtherSEC
8-K filing covering items 1.01, 2.02, 7.01, 8.01, 9.01
- Oct 15Securities offeringSEC
Filed 424B5 prospectus supplement.
- Sep 21DealSEC
8-K item 1.01: entered into material definitive agreement.
- Aug 13Trial initiationClinicalTrials.gov
Exscientia (Recursion subsidiary) initiates Phase 1 dose-finding trial of EXS73565 in relapsed/refractory B-cell malignancies (NCT06980116, recruiting).
- Aug 13Trial initiationClinicalTrials.gov
Recursion subsidiary Exscientia updates NCT05985655 Phase 1/2 trial of GTAEXS617 in advanced solid tumors to recruiting status.